A Phase 1 Study To Evaluate The Safety, Pharmacokinetics, And Pharmacodynamics Of PF-04449913, An Oral Hedgehog Inhibitor, Administered As Single Agent In Select Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 11 Nov 2014
At a glance
- Drugs Glasdegib (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Biomarker
- Sponsors Pfizer
- 14 Feb 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 04 Jan 2013 Planned end date changed from 1 Dec 2012 to 1 Jan 2013 as reported by ClinicalTrials.gov.
- 03 Oct 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.